New Location will be Marken's Third in Germany
and Eleventh in Europe.
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2018 /PRNewswire/ — Marken today announced it will open a third branch in Germany in the first quarter of 2018 to meet new demands in the region. The new branch will be located in Stuttgart, joining Marken's existing German locations in Frankfurt and Hamburg. The Stuttgart location will be more than 600m² and feature office and warehouse space to cover the increased client demand and volume in the area. Together, the three branches will employ more than 100 people in Germany, and offer Marken's full range of services.
The new Stuttgart branch will partner with clients and investigator sites to collect and ship drug products, clinical trial materials and biological samples. It will provide temperature controlled solutions as well as contain a package conditioning area. Marken's unique GMP depot services will continue from the Frankfurt location.
Bengt-Simon Feth, General Manager, Germany, said, "With the close proximity to the Stuttgart airport, Marken will be able to reduce the lead time to deliver conditioned packaging to clients within south Germany. This will further strengthen our relationships with our pharmaceutical clients and provide more operational flexibility within the Marken network."
Many of the world's largest pharmaceutical companies are located in Germany and its central location helps make it one of the most active clinical trial markets in Western Europe. The clinical trial supply and logistics market in Germanyis expected to grow 7 percent from 2016 to 2021, which much of the growth driven by demand for biopharmaceutical trial logistics.i
Wes Wheeler, Marken's Chief Executive Officer, commented, "Marken continues to grow ahead of the market to meet the demands of clinical trials clients and their supply chain needs around the world. Our new location in Stuttgartdemonstrates our commitment to ensuring that we continue to build our network to provide our clients with more options and flexibility to help their clinical trials succeed."
i Visiongain 2017